can you have withdrawals from semaglutide Frontiers Impact of semaglutide withdrawal on

CAGRISEMA This GLP-1/amylin-based combination is under investigation & reflects a strategy aimed at enhancing satiety and reducing caloric intake through complementary mechanisms GAME-CHANGERS The broader message for specialists in cardiology, neurology, endocrinology, internal medicine, vascular medicine, and primary care is that obesity treatment is increasingly becoming a cardiometabolic intervention, not only a weight-loss intervention

Both disproportionality analyses confirmed this heightened risk: ROR analysis showed a statistically significant association (ROR = 1.81, 95% CI 1.622.03), while BCPNN yielded an information component of IC = 0.85 (IC025 = 0.69), both indicating substantially greater renal impairment risks in this older population treated with the combination therapy

And when you look at the potential pros and cons of these GLP-1 agonists, they dont always make sense

CT-388 (5 trials) is entering Phase 3

Q., Mao, X

Time Point Week 13 What Trials Saw Early visceral fat decrease begins (interim trial readouts)